An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas

BMC Clinical Pathology

Rajgopal Achuthan¹  Ian M Carr²  Alexander F Markham¹  Rashida Anwar²  William Merchant¹  Kieran Horgan¹  Sarah Perry²  Edlo T Verghese²  Christine P Diggle²  Nader Touqan¹ 

[1] Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK;School of Medicine, University of Leeds, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds LS9 7TF, UK

关键词: Targeted therapy;    P53;    MDMX;    MDM2;    Liposarcoma;   

Others  :  1084720
DOI  :  10.1186/1472-6890-13-32

 received in 2013-07-25, accepted in 2013-12-09,  发布年份 2013

【 摘 要 】

Background

Inactivation of wild type P53 by its main cellular inhibitors (MDM2 and MDMX) is a well recognised feature of tumour formation in liposarcomas. MDM2 over-expression has been detected in approximately 80% of liposarcomas but only limited information is available about MDMX over-expression. To date, we are not aware of any study that has described the patterns of MDM2 and MDMX co-expression in liposarcomas. Such information has become more pertinent as various novel MDM2 and/or MDMX single and dual affinity antagonist compounds are emerging as an alternative approach for potential targeted therapeutic strategies.

Methods

We analysed a case series of 61 fully characterized liposarcomas of various sub-types by immunohistochemistry, to assess the expression levels of P53, MDM2 and MDMX, simultaneously. P53 sequencing was performed in all cases that expressed P53 protein in 10% or more of cells to rule out mutation-related over-expression.

Results

50 cases over-expressed MDM2 and 42 of these co-expressed MDMX at varying relative levels. The relative expression levels of the two proteins with respect to each other were subtype-dependent. This apparently affected the detected levels of P53 directly in two distinct patterns. Diminished levels of P53 were observed when MDM2 was significantly higher in relation to MDMX, suggesting a dominant role for MDM2 in the degradation of P53. Higher levels of P53 were noted with increasing MDMX levels suggesting an interaction between MDM2 and MDMX that resulted in a reduced efficiency of MDM2 in degrading P53. Of the 26 cases of liposarcoma with elevated P53 expression, 5 were found to have a somatic mutation in the P53 gene.

Conclusions

The results suggest that complex dynamic interactions between MDM2 and MDMX proteins may directly affect the cellular levels of P53. This therefore suggests that careful characterization of both these markers will be necessary in tumours when considering in vivo evaluation of novel blocker compounds for MDM proteins, as a therapeutic strategy to restore wild type P53 function.

【 授权许可】

   
2013 Touqan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Grimer R, Judson I, Peake D, Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma 2010, 2010:506182.
• [2]Teodoro JG, Evans SK, Green MR: Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007, 85(11):1175-1186.
• [3]Crozat A, Aman P, Mandahl N, Ron D: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363(6430):640-644.
• [4]Conyers R, Young S, Thomas DM: Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011, 2011:483154.
• [5]Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004, 52(2):103-116.
• [6]Taubert H, Meye A, Wurl P: Soft tissue sarcomas and p53 mutations. Mol Med 1998, 4(6):365-372.
• [7]Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53(10):2231-2234.
• [8]Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM: Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A 2007, 104(30):12365-12370.
• [9]Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14(17):5318-5324.
• [10]Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, Boiocchi M, Fletcher CD: Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 1997, 181(1):8-13.
• [11]Taubert H, Koehler T, Meye A, Bartel F, Lautenschlager C, Borchert S, Bache M, Schmidt H, Wurl P: MDM2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol Med 2000, 6(1):50-59.
• [12]Pilotti GT, Lavarino C: Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997, 181:14-24.
• [13]Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, et al.: MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996, 15(19):5349-5357.
• [14]Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE: Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 2006, 363(2):433-450.
• [15]Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM: A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006, 9(4):273-285.
• [16]Jackson MW, Berberich SJ: MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 2000, 20(3):1001-1007.
• [17]Kawai H, Wiederschain D, Yuan ZM: Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 2003, 23(14):4939-4947.
• [18]Lenos K, Jochemsen AG: Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011, 2011:876173.
• [19]Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM: Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002, 277(22):19251-19254.
• [20]Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M: HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 2003, 100(21):12009-12014.
• [21]Sharp DA, Kratowicz SA, Sank MJ, George DL: Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999, 274(53):38189-38196.
• [22]Wang X, Wang J, Jiang X: MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 2011, 286(27):23725-23734.
• [23]Migliorini D, Danovi D, Colombo E, Carbone R, Pelicci PG, Marine JC: Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 2002, 277(9):7318-7323.
• [24]Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, Schmidt H, Wurl P, Taubert H, Hauptmann S: Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 2005, 117(3):469-475.
• [25]Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O: Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 2012, 119(5):1013-1022.
• [26]Ito M, Barys L, O’Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S, Choong PF, Dickinson I, Crowe P, et al.: Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011, 17(3):416-426.
• [27]Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG: Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001, 61(5):1839-1842.
• [28]Barakat K, Mane J, Friesen D, Tuszynski J: Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J Mol Graph Model 2010, 28(6):555-568.
• [29]Macchiarulo A, Pellicciari R: MDM2/MDMX inhibitor peptide: WO2008106507. Expert Opin Ther Pat 2009, 19(5):721-726.
• [30]Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schonbrunn E, Chen J: Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 2010, 285(3):2174-2183.
• [31]Pazgier M, Liu M, Zou G, Yuan W, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W: Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 2009, 106(12):4665-4670.
• [32]Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA: High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 2009, 8(8):1176-1184.
• [33]Zak K, Pecak A, Rys B, Wladyka B, Domling A, Weber L, Holak TA, Dubin G: Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat 2013, 23(4):425-448.
• [34]Li Q, Lozano G: Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2013, 19(1):34-41.
• [35]Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, et al.: Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 2012, 109(29):11788-11793.
• [36]Carr IM, Camm N, Taylor GR, Charlton R, Ellard S, Sheridan EG, Markham AF, Bonthron DT: GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms. J Med Genet 2011, 48(2):123-130.
• [37]Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG: Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2001, 2(11):1029-1034.
• [38]Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O’Connor R, Maki R, Viale A, Sander C, et al.: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007, 67(14):6626-6636.
• [39]Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM: Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009, 62(12):1127-1135.
• [40]Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M: Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol 2000, 13(9):994-1004.